| ID | 117974 |
| Title Alternative | Effect of ipragliflozin on carotid intima-media thickness in type 2 diabetes patients
|
| Author |
Tanaka, Atsushi
Saga University
Sata, Masataka
Tokushima University
Tokushima University Educator and Researcher Directory
KAKEN Search Researchers
Okada, Yosuke
University of Occupational and Environmental Health
Teragawa, Hiroki
JR Hiroshima Hospital
Eguchi, Kazuo
Saitama Red Cross Hospital
Taguchi, Isao
Dokkyo Medical University
Matsunaga, Kazuo
Imari-Arita Kyoritsu Hospital
Kanzaki, Yumiko
Osaka Medical and Pharmaceutical University
Yoshida, Hisako
Osaka Metropolitan University
Ishizu, Tomoko
University of Tsukuba
Ueda, Shinichiro
University of the Ryukyus
Kitakaze, Masafumi
Hanwa Daini Senboku Hospital
Murohara, Toyoaki
Nagoya University
Node, Koichi
Saga University
|
| Keywords | Atherosclerosis
Carotid intima-media thickness
Ipragliflozin
Type 2 diabetes
|
| Content Type |
Journal Article
|
| Description | Aims
To examine the effects of a 24-month treatment with ipragliflozin on carotid intima-media thickness (IMT) in type 2 diabetes patients. Methods and results In this multicenter, prospective, randomized, open-label, and blinded-endpoint investigator-initiated clinical trial, adults with type 2 diabetes and haemoglobin A1C (HbA1c) of 6.0–10.0% (42–86 mmol/mol) were randomized equally to ipragliflozin (50 mg daily) and non-sodium-glucose cotransporter-2 (SGLT2) inhibitor use of standard-care (control group) for type 2 diabetes and were followed-up to 24 months. The primary endpoint was the change in mean common carotid artery IMT (CCA-IMT) from baseline to 24 months. A total of 482 patients were equally allocated to the ipragliflozin (N = 241) and control (N = 241) groups, and 464 patients (median age 68 years, female 31.7%, median type 2 diabetes duration 8 years, median HbA1c 7.3%) were included in the analyses. For the primary endpoint, the changes in the mean CCA-IMT from baseline to 24 months were 0.0013 [95% confidence interval (CI), −0.0155–0.0182] mm and 0.0015 (95% CI, −0.0155–0.0184) mm in the ipragliflozin and control groups, respectively, with an estimated group difference (ipragliflozin-control) of −0.0001 mm (95% CI, −0.0191–0.0189; P = 0.989). A group difference in HbA1c change at 24 months was also non-significant between the treatment groups [−0.1% (95% CI, −0.2–0.1); P = 0.359]. Conclusion Twenty-four months of ipragliflozin treatment did not affect carotid IMT status in patients with type 2 diabetes recruited in the PROTECT study, relative to the non-SGLT2 inhibitor-use standard care for type 2 diabetes. |
| Journal Title |
European Heart Journal - Cardiovascular Pharmacotherapy
|
| ISSN | 20556845
|
| Publisher | Oxford University Press|European Society of Cardiology
|
| Volume | 9
|
| Issue | 2
|
| Start Page | 165
|
| End Page | 172
|
| Published Date | 2022-10-29
|
| Rights | This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
|
| EDB ID | |
| DOI (Published Version) | |
| URL ( Publisher's Version ) | |
| FullText File | |
| language |
eng
|
| TextVersion |
Publisher
|
| departments |
Medical Sciences
|
